A detailed history of Truist Financial Corp transactions in Genmab A/S stock. As of the latest transaction made, Truist Financial Corp holds 45,176 shares of GMAB stock, worth $904,875. This represents 0.0% of its overall portfolio holdings.

Number of Shares
45,176
Previous 64,656 30.13%
Holding current value
$904,875
Previous $1.62 Million 32.2%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$23.84 - $28.48 $464,403 - $554,790
-19,480 Reduced 30.13%
45,176 $1.1 Million
Q2 2024

Aug 20, 2024

BUY
$25.13 - $30.27 $50 - $60
2 Added 0.0%
64,656 $1.62 Million
Q1 2024

May 10, 2024

BUY
$26.43 - $32.77 $213,607 - $264,847
8,082 Added 14.29%
64,654 $1.93 Million
Q4 2023

Feb 02, 2024

SELL
$27.94 - $35.44 $162,191 - $205,729
-5,805 Reduced 9.31%
56,572 $1.8 Million
Q3 2023

Nov 14, 2023

BUY
$35.27 - $42.24 $1.71 Million - $2.05 Million
48,623 Added 353.52%
62,377 $2.2 Million
Q2 2023

Aug 01, 2023

SELL
$37.4 - $42.94 $2,281 - $2,619
-61 Reduced 0.44%
13,754 $522,000
Q1 2023

May 05, 2023

SELL
$34.88 - $43.22 $238,369 - $295,365
-6,834 Reduced 33.1%
13,815 $521,000
Q4 2022

Feb 17, 2023

BUY
$33.8 - $47.06 $2,399 - $3,341
71 Added 0.35%
20,649 $875,000
Q3 2022

Oct 26, 2022

BUY
$31.52 - $373.61 $175,503 - $2.08 Million
5,568 Added 37.1%
20,578 $662,000
Q2 2022

Jul 22, 2022

SELL
$26.83 - $38.57 $37,776 - $54,306
-1,408 Reduced 8.58%
15,010 $488,000
Q1 2022

Apr 22, 2022

SELL
$30.95 - $39.68 $83,348 - $106,858
-2,693 Reduced 14.09%
16,418 $594,000
Q4 2021

Feb 14, 2022

SELL
$35.87 - $47.12 $71,847 - $94,381
-2,003 Reduced 9.49%
19,111 $756,000
Q3 2021

Nov 05, 2021

BUY
$41.55 - $48.72 $222,334 - $260,700
5,351 Added 33.95%
21,114 $923,000
Q2 2021

Aug 16, 2021

SELL
$32.88 - $44.57 $75,426 - $102,243
-2,294 Reduced 12.7%
15,763 $644,000
Q1 2021

May 17, 2021

BUY
$30.92 - $44.4 $54,728 - $78,588
1,770 Added 10.87%
18,057 $593,000
Q4 2020

Feb 18, 2021

BUY
$33.66 - $40.76 $14,305 - $17,323
425 Added 2.68%
16,287 $662,000
Q3 2020

Nov 13, 2020

SELL
$33.07 - $38.68 $73,845 - $86,372
-2,233 Reduced 12.34%
15,862 $580,000
Q2 2020

Aug 14, 2020

BUY
$20.05 - $33.89 $93,974 - $158,842
4,687 Added 34.96%
18,095 $613,000
Q1 2020

May 15, 2020

BUY
$17.15 - $25.22 $47,711 - $70,162
2,782 Added 26.18%
13,408 $284,000
Q4 2019

Feb 14, 2020

BUY
$18.88 - $24.14 $200,618 - $256,511
10,626 New
10,626 $237,000

Others Institutions Holding GMAB

About GENMAB A/S


  • Ticker GMAB
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 658,292,992
  • Market Cap $13.2B
  • Description
  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...
More about GMAB
Track This Portfolio

Track Truist Financial Corp Portfolio

Follow Truist Financial Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Truist Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Truist Financial Corp with notifications on news.